Making practical markets for vaccines

September 12, 2005

Two papers published on September 13 in PLoS Medicine raise concerns about whether world leaders are getting good advice on how best to fund the development and delivery of new vaccines.

Donald Light, Professor of comparative health care systems at the University of Medicine & Dentistry of New Jersey, discusses the report Making Markets for Vaccines produced by the Centre for Global Development and the Gates Foundation Working Group for Making Markets for Vaccines. Professor Light was a member of the CGD/Gates Foundation "Pull" Mechanisms Working Group for the report but finding the report impractical, he declined to endorse it. For this, he and others who dissented were de-listed as members in the report.

In his essay, Professor Light explains why he thinks the report's recommendations give poor advice to donor nations such as the United States and the U.K. He believes that they favor large pharmaceutical firms, delay saving lives, spend donations wastefully, and reward secrecy rather than sharing.

Professor Light reviews evidence to show that an advanced commitment is unlikely to induce much basic research to discover new, effective vaccines. Direct funding, such as the Gates Foundation's many initiatives, is faster and much cheaper than multi-billion dollar promises of future purchases. Professor Light recommends using advanced purchase commitments as a complement to paying for research and development, and he argues that terms should build in financial support as well as expert help to strengthen the public health delivery systems of recipient nations. Extensive delivery problems were not discussed and are not part of the report's recommended design. Light concludes that "advanced purchase commitments are a good idea when applied where they work best: on existing vaccines that could save millions from suffering and dying now. It seems morally dubious for a foundation or nation to do otherwise."

In a second essay, Jon Andrus and John Fitzsimmons, who direct the Vaccine Fund for the Pan American Health Organization, discuss their organization's priority to ensure the delivery of effective vaccines, and emphasize that equity is a crucial part of ensuring delivery. They discuss the challenges of making practical markets for vaccines, particularly of introducing new and underutilized ones such that they are available to children and families who need them most. They highlight the principles of access, accelerated regional disease control, and the development of a public-health infrastructure, and argue that a successful approach requires high-level political commitment. They conclude that "for vaccines, the challenge has always been, and will continue to be, to ensure that all communities benefit from the potential impact of these technologies."
-end-
Citations:

1) Light DW (2005) Making practical markets for vaccines. PLoS Med 2(10): e271.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0020271

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-02-10-light.pdf

2) Andrus JK, Fitzsimmons J (2005) Introduction of new and underutilized vaccines: Sustaining access, disease control, and infrastructure development. PLoS Med 2(10): e286.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0020286

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-02-10-andrus.pdf

CONTACTS:
Donald W. Light
University of Medicine & Dentistry of New Jersey
1-609-915-1588
dlight@princeton.edu

Jon Andrus
Pan American Health Organization
1-202-974-3635 (fax)
andrusjo@paho.org PLEASE MENTION PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES. THANK YOU. All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

PLOS

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.